66 completed, 13 terminated, 9 withdrawn, 7 recruiting. 23 Phase 3, 22 Phase 4, 20 Phase 2, 16 Phase 1, 2 Not applicable.
Follow Dimethyl Fumarate: new trials by email Literature Review of Dimethyl Fumarate trials Research Report on Dimethyl Fumarate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) Diroximel Fumarate, Dimethyl Fumarate, Fingolimod - Relapsing Forms of Multiple Sclerosis | Phase 3 | Not yet recruiting | Biogen | 185 | 2026-11-16 | 2026-03-19 |
| A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis Rocbrutinib, Dimethyl Fumarate - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 30 | 2026-08-01 | 2026-08-20 |
| A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) - Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy | Phase 3 | Recruiting | University Hospital, Montpellier | 250 | 2026-06-15 | 2026-06-23 |
| Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease dimethyl fumarate - MCI, MCI-AD, Early Stage Alzheimer's Disease | Phase 2 | Recruiting | Medical University of Lodz | 30 | 2024-10-28 | 2025-02-27 |
| A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS) Diroximel Fumarate, Dimethyl Fumarate, Disease-Modifying Therapies (DMTs) - Multiple Sclerosis | Active not recruiting | Biogen | 10500 | 2024-06-08 | 2025-10-16 | |
| Dimethyl Fumarate in Adrenomyeloneuropathy Placebo, Dimethyl fumarate - Adrenomyeloneuropathy Without Cerebral Involvement | Phase 2 / Phase 3 | Active not recruiting | Pujol, Aurora, M.D. | 40 | 2024-04-23 | 2026-06-17 |
| Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) Diroximel Fumarate, Avonex, Tysabri - Multiple Sclerosis | Recruiting | Biogen | 908 | 2023-10-27 | 2026-08-11 | |
| Dimethyl Fumarate Treatment for Intracranial Unruptured Aneurysms. Dimethyl fumarate, Placebo - Intracranial Aneurysm, Aneurysm, Brain | Phase 4 | Completed | Beijing Tiantan Hospital | 60 | 2023-07-31 | 2026-08-20 |
| A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China Dimethyl fumarate - Multiple Sclerosis | Phase 4 | Completed | Biogen | 60 | 2023-06-09 | 2025-05-16 |
| Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity) Vumerity, Tecfidera - Multiple Sclerosis (MS) Relapsing Remitting | Active not recruiting | University of Colorado, Denver | 11 | 2023-03-07 | 2026-08-11 | |
| A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis ofatumumab, glatiramer acetate, interferon β1 - Relapsing Multiple Sclerosis | Recruiting | Novartis Pharmaceuticals | 800 | 2022-05-10 | 2026-07-30 | |
| IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study IMCY-0141, Placebo, Dimethyl Fumarate - Multiple Sclerosis, Relapsing-Remitting | Phase 1 / Phase 2 | Unknown | Imcyse SA | 150 | 2022-04-12 | 2024-03-08 |
| Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy Dimethyl Fumarate (TECFIDERA™), No active : no treatment - Age-related Macular Degeneration (AMD) | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 90 | 2022-02-07 | 2026-02-04 |
| Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke Dimethyl Fumarate - Acute Ischemic Stroke | Phase 1 / Phase 2 | Unknown | Xuanwu Hospital, Beijing | 50 | 2021-12-01 | 2022-06-06 |
| Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke Dimethyl fumarate - Acute Ischemic Stroke | Phase 1 / Phase 2 | Terminated | Xuanwu Hospital, Beijing | 2 | 2021-12-01 | 2023-10-25 |
| Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS Ofatumumab, First line DMT - Multiple Sclerosis | Phase 3 | Completed | Novartis Pharmaceuticals | 185 | 2021-07-23 | 2026-03-03 |
| Dimethyl Fumarate for the Treatment of Intracerebral Hemorrhage Dimethyl fumarate, Placebo - Intracerebral Hemorrhage | Phase 2 | Withdrawn | Xuanwu Hospital, Beijing | 2021-06-01 | 2023-10-25 | |
| Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke Dimethyl Fumarate, Placebo - Acute Ischemic Stroke | Phase 2 | Withdrawn | Xuanwu Hospital, Beijing | 2021-06-01 | 2023-10-25 | |
| Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera Dimethyl fumarate - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Completed | Biogen | 1507 | 2021-03-10 | 2023-10-23 | |
| Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis. Dimethyl Fumarate 240 MG [Tecfidera] - Multiple Sclerosis | Completed | IRCCS Centro Neurolesi Bonino Pulejo | 52 | 2021-02-24 | 2024-10-15 |
Showing 20 of 107. Sign in to see all of them.
Multiple Sclerosis (47) · Multiple Sclerosis, Relapsing-Remitting (42) · Psoriasis (5) · Recurrence (5) · Ischemic Stroke (3) · Multiple Sclerosis, Chronic Progressive (3) · Neurologic Manifestations (2) · Alzheimer Disease (1) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · COVID-19 (1) · Carcinoma, Basal Cell (1) · Cardiovascular Diseases (1) · Cerebral Hemorrhage (1) · Community-Acquired Pneumonia (1)
Biogen (48) · Xuanwu Hospital, Beijing (4) · Almirall, S.A. (3) · Banner Life Sciences LLC (2) · Multiple Sclerosis Center of Northeastern New York (2) · Novartis Pharmaceuticals (2) · University Hospital Muenster (2) · University at Buffalo (2) · AbbVie (1) · Amsterdam UMC, location VUmc (1) · Anders Svenningsson (1) · Assistance Publique - Hôpitaux de Paris (1) · Beijing Tiantan Hospital (1) · Brigham and Women's Hospital (1) · Central Hospital, Nancy, France (1)
United States (46) · Germany (23) · Poland (17) · Czechia (15) · France (14) · United Kingdom (13) · Italy (12) · Belgium (11) · Canada (11) · Spain (11) · Netherlands (8) · Slovakia (8) · Australia (7) · Bulgaria (7) · Austria (6)
Anders Svenningsson, MD, PhD (2) · Adrian Tanew, MD (1) · Anna Fogdell-Hahn, PhD (1) · Anne Cross, MD (1) · Annegret Kuhn, Prof. Dr. (1) · Annette Langer-Gould, MD, PhD (1) · Carlos Casasnovas, MD, PhD (1) · Daniel Ontaneda, MD, MSc (1) · Daniel Pelletier, MD (1) · Darin T Okuda, MD (1) · De-Cai Tian, M.D., Ph.D. (1)
PMID 30918100, PMID 24131282, PMID 26932146, PMID 32426039, PMID 26526385, PMID 27733070, PMID 28751099, PMID 28770420, PMID 37061656, PMID 39570545, PMID 18970976, PMID 19073949, PMID 22992072, PMID 22992073, PMID 24139424, PMID 25315404, PMID 25999183, PMID 26049148, PMID 29159204, PMID 29524759, PMID 29681490, PMID 29800466, PMID 30206820, PMID 30447891, PMID 30470580, PMID 30616596, PMID 30870983, PMID 31033034, PMID 31075187, PMID 31391949, PMID 31832225, PMID 31953790, PMID 32678530, PMID 33031652, PMID 33031764, PMID 33225410, PMID 33394942, PMID 33545096, PMID 33796143, PMID 33797063, PMID 33933206, PMID 34000257, PMID 34013969, PMID 34429340, PMID 34473343, PMID 34658014, PMID 34672950, PMID 34800427, PMID 34815321, PMID 35151397
2014 (5), 2016 (4), 2015 (3), 2017 (2), 2019 (2), 2008 (1), 2018 (1), 2023 (1), P30CA016059 (1)